Biologics Outsourcing Global Market - Forecast to 2028

Publishing Date : October, 2020
Report Code : HCPH0110
Price:
Single license $7,200
Site license $9,000
Global license $12,000


Note: The report would be dispatched after confirmation of payment

The biologics outsourcing global market is expected to grow at low teen CAGR to reach $87.5 billion by 2028. Biologics are the therapeutic entities composed of sugars, proteins, or nucleic acids and made from natural sources such as human, animal or microorganisms. Biologics also include live attenuated microorganisms (vaccines), allergenic extracts (allergy shots), human cells and tissues (for transplantation), cell and gene therapeutics. Similar to the conventional therapeutics, these drugs help in treating several diseases but are highly specific and more efficient in their disease healing mechanisms. The biologic entities like monoclonal antibodies and recombinant proteins target specific areas during their molecular mechanism of disease curing.

Even though biologics are highly expensive when compared to the conventional small molecule drugs, these target specific therapeutics have proven to be very beneficial for patients and also ensure higher profit margins to the drug manufacturers. The escalating adoption of biologics and elevating demand for the highly efficient biotherapeutics from the value-centric patient population across the globe, increasing investments on research and developmental activities of biologics and advanced, next-generation biotherapeutics, a favorable and streamlined regulatory environment that is expediting the novel product approval process and the expansion of biosimilar market have all led to the rapid growth of the biopharmaceutical market. Due to the increasing demand for biologics drugs and increased regulatory approvals for these drugs, there is huge demand for biologics manufacture and testing at various levels of clinical studies as well as commercial supply. This fast pacing biologic industry coupled with insufficient or lack of in house biologic development and manufacturing capabilities and capacities of biopharmaceutical companies has spurred these companies to outsource the different parts of biologic development and manufacturing process to highly efficient service providing organizations. The Large Biopharma companies are coming up with strategies to cut down on their operational costs and concentrate more on their core competencies by outsourcing this piece of work to contract research organizations (CROs), contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs). These organizations bridge the gap between demand and supply and ensure the drug discovery and manufacturing process gets much faster and convenient; thus bringing the life-saving drugs to the market and the needy patients at the earliest.

In 2019, seven out of the 10 blockbuster drugs were biologics, outnumbering small molecule drugs. Some of the top-selling biologics in 2019 include Humira ($19.1 billion), Keytruda ($11.0 billion), Avastin ($7.28 billion) and Opdivo ($7.20 billion). The growth of biologics market indirectly indicates the huge demand for services spanning all stages of biologic development starting from the preclinical stage to commercial manufacturing. The high complexity associated with development and manufacturing of biologics and requirement of specialized equipments and skills for biomanufacturing is prompting the biopharma companies to turn to outsourcing as a viable option. Thus the CMO’s offering quality compliant, rapid bioproduction and supply services, scalable and flexible capacities with stable capabilities at competitive costs will become an integral part of the biopharmaceutical company. Various stages of biological development require different types of services as listed below.
Discovery services- Includes lead identification and validation for identifying possible drug candidates targeting specific diseases. The process further involves steps such as target validation, screening preparation, hit generation and lead selection, lead optimization and characterization and finally lead selection.
Preclinical development services- Involves in-vitro and in-vivo studies of the biologic drug candidates before testing them on humans to test the safety, efficacy and biological functionality against the disease target. Preclinical services include cell line engineering, process development, product analytical characterization, cGMP cell banking, cell line characterization, animal model assay development and testing services.
Clinical development- Clinical development includes testing potential drug candidates on humans in phase I, II and II trials. Services at this stage include cGMP grade clinical supply of biologics such as MAb, or recombinant protein, stability testing, fill/finish and regulatory support.

Commercialization- Once the drug has passed all the necessary approvals, the manufacture, marketing and sale of commercial quantities is performed. Outsourcing partners here manufacture the commercial supply for product launch and sale.

The biologics outsourcing global market has been segmented based on the developmental phase, product, end users and geography. Among the discovery, pre-clinical, clinical and commercial phases of biologics development, Commercial Phase outsourcing commanded the largest revenue in 2020. It is also the fastest growing segment and is expected to grow at low teen CAGR during the forecasted period. The biological outsourcing market by product type is segmented into Antibody, Proteins, Vaccines, Gene therapy, cell therapy and others. Among these, the antibody outsourcing segment accounted for the largest share of revenue in 2020 and is expected to grow at low teen CAGR during the forecasted period. Gene therapeutics segment is expected to be the fastest emerging market growing at low teen CAGR during the forecasted period. Based on end – users, the biologics outsourcing market is segmented into Therapeutics, Diagnostics and Research. Therapeutics is the largest and fastest growing segment and is expected to grow at low teen CAGR from 2020 to 2028. Geographically, North America dominated the biologics outsourcing market with the highest revenue in 2020 and is expected to grow at double digit CAGR from 2020 to 2028. Asia Pacific region is expected to be the fastest emerging market growing at mid teen CAGR during the forecasted period.

The report specifically emphasizes on the rapidly evolving and high growth potential biologics contract manufacturing services market and cell line development services market. Biologics contract biomanufacturing services global market is expected to reach $57.1 billion by 2028 growing at a low teen CAGR from 2020 to 2028. The cell line development service global market is expected to reach $1,702.2 million by 2028 growing at a double digit CAGR from 2020 to 2028.

  • 1     BIOLOGICS OUTSOURCING GLOBAL MARKET
    • 1.1     INTRODUCTION
    • 1.2     LANDSCAPE OF BIOLOGICS MARKET
    • 1.3     RISE OF BIOSIMILARS
    • 1.4     BIOSIMILARS GLOBAL MARKET, BY REGION
    • 1.5     BIOLOGICS GLOBAL MARKET
    • 1.6     TOP DESTINATION FOR BIOLOGICS OUTSOURCING
      • 1.6.1     CHINA BIOLOGICS OUTSOURCING MARKET
      • 1.6.2     INDIA BIOLOGICS OUTSOURCING MARKET
      • 1.6.3     CHINA VS INDIA - BIOLOGICS MARKET
      • 1.6.4     REGULATIONS AND GOVERNMENT INITIATIVES
      • 1.6.5     CAPABILITIES AND TECHNOLOGIES
  • 2     MARKET ANALYSIS
    • 2.1     INTRODUCTION
    • 2.2     FACTORS INFLUENCING MARKET
      • 2.2.1     DRIVERS AND OPPORTUNITIES
        • 2.2.1.1     INCREASING TREND OF OUTSOURCING
        • 2.2.1.2     ADVANCED BIOPROCESSING CAPABILITIES OF BIOSERVICE PROVIDERS
        • 2.2.1.3     EMERGENCE OF NEXT GENERATION BIOLOGICS
        • 2.2.1.4     ESCALATING APPROVALS AND UPTAKE OF BIOSIMILARS
        • 2.2.1.5     INCREASING APPROVALS AND ADOPTION OF BIOLOGICS
        • 2.2.1.6     INCREASING R&D EXPENDITURES
        • 2.2.1.7     INCREASING PREVALENCE OF CHRONIC, COMMUNICABLE AND AUTOIMMUNE DISEASES
        • 2.2.1.8     DEVELOPMENT OF PERSONALIZED AND ORPHAN INDICATION THERAPIES
      • 2.2.2     RESTRAINTS AND THREATS
        • 2.2.2.1     INCREASING FOCUS ON IN-HOUSE BIOLOGICS MANUFACTURING
        • 2.2.2.2     HUGE CAPITAL INVESTMENTS FOR CAPACITY AND CAPABILITY DEVELOPMENT
        • 2.2.2.3     COMPLIANCE WITH STRINGENT REGULATORY GUIDELINES
        • 2.2.2.4     CONCERNS ABOUT IP PROTECTION
        • 1.2.2.5      COMPETITION AND TREND OF OUTSOURCING OF LOW VOLUME BIOLOGICS
  • 3     BIOLOGICS OUTSOURCING GLOBAL MARKET, MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     DISCOVERY AND PRE-CLINICAL DEVELOPMENT PROCESS
    • 3.3     BIOLOGICS OUTSOURCING GLOBAL MARKET, BY PRODUCT TYPE
      • 3.3.1     ANTIBODY
        • 3.3.1.1     MONOCLONAL ANTIBODY
        • 3.3.1.2     BISPECIFIC ANTIBODY
        • 3.3.1.3     ANTIBODY DRUG CONJUGATES
        • 3.3.1.4     OTHERS (POLYCLONAL ANTIBODY, ANTIBODY FRAGMENTS)
      • 3.3.2     RECOMBINANT PROTEIN
      • 3.3.3     FUSION PROTEINS
        • 3.3.3.1     HORMONES
        • 3.3.3.2     RECOMBINANT ENZYMES
        • 3.3.3.3     OTHERS (CYTOKINES, PEPTIDES)
      • 3.3.4     VACCINES
      • 3.3.5     GENE THERAPY
      • 3.3.6     CELL THERAPY
        • 3.3.6.1     OTHERS (TRANSGENIC PROTEINS AND OTHER RECOMBINANT PRODUCTS)
    • 3.4     BIOLOGICS OUTSOURCING GLOBAL MARKET, BY ENDUSERS
      • 3.4.1     THERAPEUTICS
      • 3.4.2     DIAGNOSTICS
      • 3.4.3     RESEARCH
    • 3.5     BIOANALYTICAL TESTING SERVICES
    • 3.6     MARKET SHARE ANALYSIS
    • 3.7     COMPANY DEVELOPMENTS
      • 3.7.1     AGREEMENT, COLLABORATIONS AND PARTNERSHIPS
      • 3.7.2     EXPANSION
      • 3.7.3     PRODUCT, TECHNOLGY AND SERVICE LAUNCH
      • 3.7.4     ACQUISITIONS
      • 3.7.5     OTHER DEVELOPMENTS
    • 3.8     SERVICE COST ANALYSIS
      • 3.8.1     ANTIBODY PRODUCTION SERVICE COSTS
      • 3.8.2     CUSTOM MONOCLONAL ANTIBODY PRODUCTION SERVICE COSTS
      • 3.8.3     CUSTOM POLYCLONAL ANTIBODY PRODUCTION SERVICE COSTS
      • 3.8.4     PROTEIN PRODUCTION SERVICE COSTS
      • 3.8.5     ADDITIONAL ANTIBODY AND PROTEIN SERVICES
      • 3.8.6     GENE EDITTING SERVICES
      • 3.8.7     CAR-T/NK PLATFORM SERVICES
  • 4     BIOLOGICS OUTSOURCING GLOBAL MARKET - BIOMANUFACTURING
    • 4.1     INTRODUCTION
    • 4.2     MARKET DYNAMICS
    • 4.3     IN HOUSE VS CMO CAPACITY
      • 4.3.1     GLOBAL BIOMANUFACTURING CAPACITY
      • 4.3.2     BIOLOGICS CONTRACT MANUFACTURING ORGANIZATIONS, BY PHASE
    • 4.4     CONTRACT BIOMANUFACTURING, BY PROCESS
      • 4.4.1     BIOMANUFACTURING BY MAMMALIAN CELL CULTURE
      • 4.4.2     MAMMALIAN CELL CULTURE BIOMANUFACTURING V/S MICROBIAL AND OTHER CELL CULTURES
      • 4.4.3     BIOMANUFACTURING BY MICROBIAL CELL CULTURE
        • 4.4.3.1     MICROBIAL CELL CULTURE CMO BIOMANUFACTURING CAPACITY
      • 4.4.4     BIOMANUFACTURING BY OTHER CELL CULTURE
    • 4.5     CONTRACT BIOMANUFACTURING GLOBAL MARKET, BY END USERS
      • 4.5.1     CONTRACT BIOMANUFACTURING OF DIAGNOSTICS
      • 4.5.2     CONTRACT BIOMANUFACTURING OF RESEARCH REAGENTS
      • 4.5.3     CONTRACT BIOMANUFACTURING OF THERAPEUTICS
        • 4.5.3.1     BIOMANUFACTURING OF ANTIBODIES
        • 4.5.3.2     BIOMANUFACTURING OF RECOMBINANT PROTEINS
        • 4.5.3.3     BIOMANUFACTURING OF VACCINES
        • 4.5.3.4     OTHER BIOLOGICS CONTRACT BIOMANUFACTURING
    • 4.6     BIOMANUFACTURING OUTSOURCING GLOBAL MARKET, BY REGION
    • 4.7     CONTRACT BIOMANUFACTURING CAPACITY PENETRATION
    • 4.8     COMPETITIVE LANDSCAPE
      • 4.8.1     CAPACITY COMPARISON
      • 4.8.2     CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY LEADING PLAYERS
      • 4.8.3     COMPANY DEVELOPMENTS
        • 4.8.3.1     AGREEMENT
        • 4.8.3.2     EXPANSION
        • 4.8.3.3     ACQUISITION
        • 4.8.3.4     COLLABORATION AND PARTNERSHIPS
        • 4.8.3.5     PRODUCT LAUNCH
        • 4.8.3.6     FACILITY APPROVALS
        • 4.8.3.7     OTHER DEVELOPMENTS
  • 5     BIOLOGICS OUTSOURCING GLOBAL MARKET - CELL LINE DEVELOPMENT
    • 5.1     INTRODUCTION
      • 5.1.1     MARKET DYNAMICS
    • 5.2     CELL LINE DEVELOPMENT
      • 5.2.1     CELL LINE CONSTRUCTION
      • 5.2.2     HOST CELL LINE ENGINEERING
      • 5.2.3     EXPRESSION SYSTEM
      • 5.2.4     TRANSIENT GENE EXPRESSION
      • 5.2.5     STABLE CELL LINE DEVELOPMENT
      • 5.2.6     SCREENING
      • 5.2.7     UPSTREAM PROCESS DEVELOPMENT
    • 5.3     HOST CELL LINES
    • 5.4     CELL LINE DEVELOPMENT SERVICES MARKET, BY EXPRESSION SYSTEM
      • 5.4.1     MICROBIAL EXPRESSION SYSTEMS
      • 5.4.2     MAMMALIAN EXPRESSION SYSTEM
      • 5.4.3     OTHERS (INSECT AND PLANT CELL)
    • 5.5     CELL LINE DEVELOPMENT SERVICES, BY CELL TYPE
      • 5.5.1     CHO
      • 5.5.2     MURINE/MOUSE MYELOMA
      • 5.5.3     BABY HAMSTER KIDNEY (BHK) CELLS
      • 5.5.4     HYBRIDOMA
      • 5.5.5     HUMAN EMBRYONIC KIDNEY (HEK) CELLS
      • 5.5.6     HUMAN EMBRYONIC RETINAL CELLS (PER.C6)
      • 5.5.7     OTHERS (E.COLI, YEAST, INSECT CELL, HT-1080, HELA CELL LINE, CAP, HKB-11, HUH-7)
    • 5.6     CELL LINE DEVELOPMENT SERVICES, BY APPLICATIONS
      • 5.6.1     RESEARCH
      • 5.6.2     BIOPRODUCTION
      • 5.6.3     DIAGNOSTICS
    • 5.7     CELL BANKING SERVICES
    • 5.8     CELL LINE CHARACTERIZATION SERVICES
    • 5.9     MARKET SHARE ANALYSIS
    • 5.10     KEY DEVELOPMENTS
      • 5.10.1     AGREEMENTS
      • 5.10.2     NEW TECHNOLOGY, PRODUCT AND SERVICE LAUNCH
      • 5.10.3     EXPANSION
      • 5.10.4     OTHER DEVELOPMENTS
  • 6     COMPANY PROFILES
    • 6.1     ABBVIE INC.
      • 6.1.1     OVERVIEW
      • 6.1.2     FINANCIALS
      • 6.1.3     SERVICE PORTFOLIO
      • 6.1.4     KEY DEVELOPMENTS
      • 6.1.5     SWOT ANALYSIS
    • 6.2     ABZENA PLC
      • 6.2.1     OVERVIEW
      • 6.2.2     FINANCIALS
      • 6.2.3     SERVICE PORTFOLIO
      • 6.2.4     KEY DEVELOPMENTS
      • 6.2.5     SWOT ANALYSIS
    • 6.3     AGC INC.
      • 6.3.1     OVERVIEW
      • 6.3.2     FINANCIALS
      • 6.3.3     SERVICE PORTFOLIO
      • 6.3.4     KEY DEVELOPMENTS
      • 6.3.5     SWOT ANALYSIS
    • 6.4     ALBANY MOLECULAR RESEARCH, INC.
      • 6.4.1     OVERVIEW
      • 6.4.2     FINANCIALS
      • 6.4.3     SERVICE PORTFOLIO
      • 6.4.4     KEY DEVELOPMENTS
      • 6.4.5     SWOT ANALYSIS
    • 6.5     BOEHRINGER INGELHEIM INTERNATIONAL GMBH
      • 6.5.1     OVERVIEW
      • 6.5.2     FINANCIALS
      • 6.5.3     SERVICE PORTFOLIO
      • 6.5.4     KEY DEVELOPMENTS
      • 6.5.5     SWOT ANALYSIS
    • 6.6     CATALENT INC.
      • 6.6.1     OVERVIEW
      • 6.6.2     FINANCIALS
      • 6.6.3     SERVICE PORTFOLIO
      • 6.6.4     KEY DEVELOPMENTS
      • 6.6.5     SWOT ANALYSIS
    • 6.7     CHARLES RIVER LABORATORIES
      • 6.7.1     OVERVIEW
      • 6.7.2     FINANCIALS
      • 6.7.3     SERVICE PORTFOLIO
      • 6.7.4     KEY DEVELOPMENTS
      • 6.7.5     SWOT ANALYSIS
    • 6.8     COGNATE BIOSERVICES INC. (COBRA BIOLOGICS)
      • 6.8.1     OVERVIEW
      • 6.8.2     FINANCIALS
      • 6.8.3     SERVICE PORTFOLIO
      • 6.8.4     KEY DEVELOPMENTS
      • 6.8.5     SWOT ANALYSIS
    • 6.9     ENVIGO
      • 6.9.1     OVERVIEW
      • 6.9.2     FINANCIALS
      • 6.9.3     SERVICE PORTFOLIO
      • 6.9.4     KEY DEVELOPMENTS
      • 6.9.5     SWOT ANALYSIS
    • 6.10     EUROFINS SCIENTIFIC S.E.
      • 6.10.1     OVERVIEW
      • 6.10.2     FINANCIALS
      • 6.10.3     SERVICE PORTFOLIO
      • 6.10.4     KEY DEVELOPMENTS
      • 6.10.5     SWOT ANALYSIS
    • 6.11     FUJIFILM HOLDINGS CORPORATION (FUJIFILM DIOSYNTH BIOTECHNOL0GIES)
      • 6.11.1     OVERVIEW
      • 6.11.2     FINANCIALS
      • 6.11.3     SERVICE PORTFOLIO
      • 6.11.4     KEY DEVELOPMENTS
      • 6.11.5     SWOT ANALYSIS
    • 6.12     GENSCRIPT BIOTECH CORPORATION
      • 6.12.1     OVERVIEW
      • 6.12.2     FINANCIALS
      • 6.12.3     SERVICE PORTFOLIO
      • 6.12.4     KEY DEVELOPMENTS
      • 6.12.5     SWOT ANALYSIS
    • 6.13     INTERTEK GROUP PLC
      • 6.13.1     OVERVIEW
      • 6.13.2     FINANCIALS
      • 6.13.3     SERVICE PORTFOLIO
      • 6.13.4     KEY DEVELOPMENTS
      • 6.13.5     SWOT ANALYSIS
    • 6.14     IQVIA HOLDINGS INC.
      • 6.14.1     OVERVIEW
      • 6.14.2     FINANCIALS
      • 6.14.3     SERVICE PORTFOLIO
      • 6.14.4     KEY DEVELOPMENTS
      • 6.14.5     SWOT ANALYSIS
    • 6.15     JSR CORPORATION
      • 6.15.1     OVERVIEW
      • 6.15.2     FINANCIALS
      • 6.15.3     SERVICE PORTFOLIO
      • 6.15.4     KEY DEVELOPMENTS
      • 6.15.5     SWOT ANALYSIS
    • 6.16     LABORATORY CORP OF AMERICA HOLDINGS
      • 6.16.1     OVERVIEW
      • 6.16.2     FINANCIALS
      • 6.16.3     SERVICE PORTFOLIO
      • 6.16.4     KEY DEVELOPMENTS
      • 6.16.5     SWOT ANALYSIS
    • 6.17     LONZA GROUP LTD.
      • 6.17.1     OVERVIEW
      • 6.17.2     FINANCIALS
      • 6.17.3     SERVICE PORTFOLIO
      • 6.17.4     KEY DEVELOPMENTS
      • 6.17.5     SWOT ANALYSIS
    • 6.18     MERCK KGA
      • 6.18.1     OVERVIEW
      • 6.18.2     FINANCIALS
      • 6.18.3     PRODUCT PORTFOLIO
      • 6.18.4     KEY DEVELOPMENTS
      • 6.18.5     SWOT ANALYSIS
    • 6.19     RENTSCHLER BIOPHARMA SE
      • 6.19.1     OVERVIEW
      • 6.19.2     FINANCIALS
      • 6.19.3     SERVICE PORTFOLIO
      • 6.19.4     KEY DEVELOPMENTS
      • 6.19.5     SWOT ANALYSIS
    • 6.20     SAMSUNG BIOLOGICS CO. LTD.
      • 6.20.1     OVERVIEW
      • 6.20.2     FINANCIALS
      • 6.20.3     SERVICE PORTFOLIO
      • 6.20.4     KEY DEVELOPMENTS
      • 6.20.5     SWOT ANALYSIS
    • 6.21     SARTORIUS GROUP
      • 6.21.1     OVERVIEW
      • 6.21.2     FINANCIALS
      • 6.21.3     SERVICE PORTFOLIO
      • 6.21.4     KEY DEVELOPMENTS
      • 6.21.5     SWOT ANALYSIS
    • 6.22     SGS SA
      • 6.22.1     OVERVIEW
      • 6.22.2     FINANCIALS
      • 6.22.3     SERVICE PORTFOLIO
      • 6.22.4     KEY DEVELOPMENTS
      • 6.22.5     SWOT ANALYSIS
    • 6.23     SYNGENE INTERNATIONAL LTD.
      • 6.23.1     OVERVIEW
      • 6.23.2     FINANCIALS
      • 6.23.3     SERVICE PORTFOLIO
      • 6.23.4     KEY DEVELOPMENTS
      • 6.23.5     SWOT ANALYSIS
    • 6.24     THERMO FISHER SCIENTIFIC INC.
      • 6.24.1     OVERVIEW
      • 6.24.2     FINANCIALS
      • 6.24.3     SERVICE PORTFOLIO
      • 6.24.4     KEY DEVELOPMENTS
      • 6.24.5     SWOT ANALYSIS
    • 6.25     WUXI APPTEC CO., LTD.
      • 6.25.1     OVERVIEW
      • 6.25.2     FINANCIALS
      • 6.25.3     SERVICE PORTFOLIO
      • 6.25.4     KEY DEVELOPMENTS
      • 6.25.5     SWOT ANALYSIS
    • 6.26     WUXI BIOLOGICS (CAYMAN) INC.
      • 6.26.1     OVERVIEW
      • 6.26.2     FINANCIALS
      • 6.26.3     SERVICE PORTFOLIO
      • 6.26.4     KEY DEVELOPMENTS
      • 6.26.5     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     PATENT EXPIRY OF BIOLOGICS (2018 – 2030)
      • TABLE 2     BIOSIMILARS GLOBAL MARKET, BY REGION, (2019-2028) ($BN)
      • TABLE 3     HIGHLIGHTS OF THE REVISED GUIDELINES
      • TABLE 4     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY REGION (2019-2028) ($BN)
      • TABLE 5     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY PRODUCT (2019-2028) ($BN)
      • TABLE 6     LIST OF BIOLOGICS APPROVED (2014-2020*)
      • TABLE 7     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY PHASE (2019-2028) ($BN)
      • TABLE 8     ANTIBODY OUTSOURCING GLOBAL MARKET REVENUE, BY PRODUCT TYPE (2019-2028) ($BN)
      • TABLE 9     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY END USERS (2019-2028) ($BN)
      • TABLE 10     AGREEMENT, COLLABORATIONS AND PARTNERSHIPS (2019 -2020)
      • TABLE 11     EXPANSIONS (2019-2020)
      • TABLE 12     PRODUCT, TECHNOLOGY AND SERVICE LAUNCH (2019-2020)
      • TABLE 13     ACQUISITIONS (2019-2020)
      • TABLE 14     OTHER DEVELOPMENTS (2019 – 2020)
      • TABLE 15     SERVICE COMPARISON MATRIX OF THE COMPANY BASED ON BIOLOGICS TYPE
      • TABLE 16     CAPACITY COMPARISON OF CONTRACT MANUFACTURING ORGANIZATIONS V’S IN-HOUSE CAPACITIES (L)
      • TABLE 17     BIOLOGICS MANUFACTURED IN MAMMALIAN CELL CULTURE
      • TABLE 18     CONTRACT MANUFACTURING ORGANIZATIONS CAPACITY, BY PROCESS (L)
      • TABLE 19     BIOLOGICS MANUFACTURED IN MICROBIAL CELL CULTURE
      • TABLE 20     BIOMANUFACTURING OUTSOURCING GLOBAL MARKET BY END USERS, (2019-2028) ($BN)
      • TABLE 21     SELECTED FDA APPROVED THERAPEUTIC PEPTIDES AND PROTEINS
      • TABLE 22     BIOMANUFACTURING OUTSOURCING GLOBAL MARKET BY REGION, (2019-2028) ($BN)
      • TABLE 23     AGREEMENT
      • TABLE 24     EXPANSION
      • TABLE 25     ACQUISITION
      • TABLE 26     COLLABORATION AND PARTNERSHIPS
      • TABLE 27     PRODUCT LAUNCH
      • TABLE 28     FACILITY APPROVALS
      • TABLE 29     OTHER DEVELOPMENTS
      • TABLE 30     COMPANY COMPARISON MATRIX, BY MANUFACTURING CAPABILITY
      • TABLE 31     CELL LINE DEVELOPMENT SERVICES MARKET, BY REGION, (2019-2028) ($MN)
      • TABLE 32     APPROVED BIOLOGICS AND CELL LINE TYPE (2014-2020)
      • TABLE 33     NUMBER OF APPROVED BIOLOGICS BY CELL LINE TYPE (2014-2020)
      • TABLE 34     CELL LINE DEVELOPMENT SERVICES MARKET, BY EXPRESSION SYSTEM, (2019-2028) ($MN)
      • TABLE 35     CELL LINE DEVELOPMENT SERVICES MARKET, BY CELL TYPE, (2019-2028) ($MN)
      • TABLE 36     CELL LINE TYPE OF SOME APPROVED BIOLOGICS MODALITIES AND CELL LINE TYPE
      • TABLE 37     CELL LINE DEVELOPMENT SERVICES MARKET, BY APPLICATION, (2019-2028) ($MN)
      • TABLE 38     CELL LINE DEVELOPMENT TECHNOLOGIES
      • TABLE 39     CELL LINE DEVELOPMENT SERVICES COST
      • TABLE 40     AGREEMENTS (2019 -2020)
      • TABLE 41     NEW TECHNOLOGY, PRODUCT AND SERVICE LAUNCH (2019-2020)
      • TABLE 42     EXPANSIONS (2019-2020)
      • TABLE 43     OTHERS (2019-2020)
      • TABLE 44     COMPARISON MATRIX OF CELL LINE DEVELOPMENT PLAYERS AND SERVICES OFFERED
      • TABLE 45     ABBVIE INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 46     ABBVIE INC.: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 47     ABBVIE INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 48     AGC INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 49     AGC INC.: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 50     AGC INC.: CHEMICALS REVENUE, BY SUB-SEGMENTS, (2018-2020) ($MN)
      • TABLE 51     AGC INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 52     BOEHRINGER INGELHEIM: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 53     BOEHRINGER INGELHEIM: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 54     BOEHRINGER INGELHEIM: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 55     CATALENT INC: TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN)
      • TABLE 56     CATALENT INC: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 57     CHARLES RIVER LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 58     CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 59     CHARLES RIVER LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 60     EUROFINS SCIENTIFIC S.E. : TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN)
      • TABLE 61     EUROFINS SCIENTIFIC S.E : TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 62     FUJIFILM HOLDINGS CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 63     FUJIFILM HOLDINGS CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 64     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 65     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
      • TABLE 66     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2017-2019) ($MN)
      • TABLE 67     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
      • TABLE 68     INTERTEK GROUP PLC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 69     INTERTEK GROUP PLC.: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 70     INTERTEK GROUP PLC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 71     IQVIA HOLDINGS INC.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 72     IQVIA HOLDINGS INC.: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 73     IQVIA HOLDINGS INC.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 74     JSR CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 75     JSR CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 76     JSR CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 77     LABORATORY CORPORATION: TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN)
      • TABLE 78     LABORATORY CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 79     LABORATORY CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 80     LONZA GROUP: TOTAL REVENUE & R&D EXPENSES (2018 -2020) ($MN)
      • TABLE 81     LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 82     LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY (2018-2020) ($MN)
      • TABLE 83     MERCK KGA: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 84     MERCK KGA: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 85     MERCK KGA: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 86     SAMSUNG BIOLOGICS CO: TOTAL REVENUE (2018-2020) ($MN)
      • TABLE 87     SAMSUNG BIOLOGICS: TOTAL REVENUE, BY GEOGRAPHY (2018-2020) ($MN)
      • TABLE 88     SAMSUNG BIOLOGICS: CONTRACT MANUFACTURING REVENUE, BY TYPE (2018-2020) ($MN)
      • TABLE 89     SARTORIUS : TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN)
      • TABLE 90     SARTORIUS: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 91     SARTORIUS: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 92     SGS SA: TOTAL REVENUE & R&D EXPENSES (2018-2020) ($MN)
      • TABLE 93     SGS SA: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 94     SGS SA: TOTAL REVENUE, BY GEOGRAPHY (2018-2020) ($MN)
      • TABLE 95     SYNGENE INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 96     SYNGENE INTERNATIONAL: TOTAL REVENUE, BY OPERATIONS, (2018-2020) ($MN)
      • TABLE 97     THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE AND R&D EXPENSES (2018-2020) ($MN)
      • TABLE 98     THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE, BY SEGMENT, (2018-2020) ($MN)
      • TABLE 99     THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE, BY PRODUCT TYPE, (2018-2020) ($MN)
      • TABLE 100     THERMO FISHER SCIENTIFIC INC.: TOTAL REVENUE, BY GEOGRAPHY (2018-2020) ($MN)
      • TABLE 101     WUXI APPTEC CO., LTD.: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 102     WUXI APPTEC CO., LTD.: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 103     WUXI APPTEC CO., LTD.: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)
      • TABLE 104     WUXI BIOLOGICS: TOTAL REVENUE AND R&D EXPENSES, (2018-2020) ($MN)
      • TABLE 105     WUXI BIOLOGICS: TOTAL REVENUE, BY SEGMENTS, (2018-2020) ($MN)
      • TABLE 106     WUXI BIOLOGICS: TOTAL REVENUE, BY GEOGRAPHY, (2018-2020) ($MN)

      LIST OF FIGURES

      • FIGURE 1     TOP SELLING DRUGS (2015 – 2019), SMALL MOLECULES V/S BIOLOGICS, (2012-2020)
      • FIGURE 2     TOP 30 BIOLOGICS PATENT EXPIRY, (2020-2032) AND RISE OF BIOSIMILARS
      • FIGURE 3     BIOLOGICS REVENUE GENERATION IN NON-TRADITIONAL THERAPIES (2018 VS 2019)
      • FIGURE 4     OUTLOOK OF BIOLOGICS GLOBAL MARKET (2019-2028) ($BN)
      • FIGURE 5     OUTLOOK OF CHINA BIOLOGICS AND BIOLOGICS OUTSOURCING MARKET (2019-2028) ($BN)
      • FIGURE 6     OUTLOOK OF INDIA BIOLOGICS AND BIOLOGICS OUTSOURCING MARKET (2019-2028) ($BN)
      • FIGURE 7     CHINA VS INDIA
      • FIGURE 8     MARKET DYNAMICS
      • FIGURE 9     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY REGION (2019-2028) ($BN)
      • FIGURE 10     BIOLOGICS OUTSOURCING GLOBAL MARKET SHARE, BY PRODUCT, (2020 V/S 2028) (%)
      • FIGURE 11     DISCOVERY BIOLOGICS OUTSOURCING MARKET SHARE, BY SERVICES 2020 (%)
      • FIGURE 12     DISCOVERY BIOLOGICS OUTSOURCING MARKET, BY SERVICE TYPE, 2020 ($MN)
      • FIGURE 13     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY PHASE (2020 V/S 2028) ($BN)
      • FIGURE 14     ANTIBODY OUTSOURCING GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2020 V/S 2028) ($BN)
      • FIGURE 15     BIOLOGICS OUTSOURCING GLOBAL MARKET REVENUE, BY END-USERS (2020 V/S 2028) ($BN)
      • FIGURE 16     BIOLOGICS OUTSOURCING GLOBAL MARKET SHARE ANALYSIS, BY MAJOR PLAYERS, 2020 (%)
      • FIGURE 17     KEY DEALS (2019-2020)
      • FIGURE 18     MARKET DYNAMICS OF CONTRACT BIOMANUFACTURING GLOBAL MARKET
      • FIGURE 19     GLOBAL MANUFACTURING CAPACITY, CGMP V’S NON-CGMP, INHOUSE V’S CMO, 2019-2028
      • FIGURE 20     CAPACITY UTILIZATION OF CONTRACT MANUFACTURING ORGANIZATIONS, BY STAGE (MILLION LITERS) (2018-2028)
      • FIGURE 21     BIOLOGICS CMO GLOBAL MARKET, BY PHASE, (2018-2028) ($BN)
      • FIGURE 22     BIOLOGICS CMO GLOBAL MARKET, BY PROCESS, (2018-2028) ($BN)
      • FIGURE 23     GLOBAL CAPACITY COMPARISON OF MAMMALIAN, MICROBIAL AND OTHER CULTURE SYSTEMS (MN L) (2018-2028)
      • FIGURE 24     CMO CAPACITY COMPARISON OF MAMMALIAN, MICROBIAL AND OTHER CULTURE SYSTEMS (MN L) (2018-2028)
      • FIGURE 25     BIO-MANUFACTURING OUTSOURCING GLOBAL MARKET, BY END USERS, (2019-2028) ($BN)
      • FIGURE 26     ADC PIPELINE FOR CANCER (2020)
      • FIGURE 27     MONOCLONAL ANTIBODY PIPELINE FOR NON-CANCER INDICATIONS (2020)
      • FIGURE 28     MONOCLONAL ANTIBODY PIPELINE FOR CANCER (2020)
      • FIGURE 29     OUTLOOK OF BIOLOGICS CMO GLOBAL MARKET SHARE, BY REGION 2020 (%) AND MANUFACTURING IN METRIC TONS, (2019-208)
      • FIGURE 30     CONTRACT BIOMANUFACTURING CAPACITY PENETRATION (2020)
      • FIGURE 31     CAPACITY COMPARISON OF TOP 15 CONTRACT MANUFACTURING ORGANIZATIONS (L)
      • FIGURE 32     CONTRACT MANUFACTURING GLOBAL MARKET SHARE, BY LEADING PLAYERS, 2020 (%)
      • FIGURE 33     KEY DEALS (2019 – 2020)
      • FIGURE 34     MARKET DYNAMICS OF CELL LINE DEVELOPMENT
      • FIGURE 35     CELL LINE DEVELOPMENT SERVICES MARKET, BY REGION, (2020 VS 2028) (%)
      • FIGURE 36     NUMBER OF APPROVED BIOLOGICS BY CELL LINE TYPE (2014-2019)
      • FIGURE 37     CELL LINE DEVELOPMENT SERVICES MARKET, BY EXPRESSION SYSTEM, (2020 V/S 2028) ($MN)
      • FIGURE 38     EXPRESSION SYSTEMS OF SOME APPROVED BIOLOGICS (2014 – 2020)
      • FIGURE 39     CELL LINE DEVELOPMENT SERVICES MARKET, BY CELL TYPE, (2020 V/S 2028) ($MN)
      • FIGURE 40     CELL LINE TYPE OF SOME APPROVED BIOLOGICS (NO’S)
      • FIGURE 41     CELL LINE TYPE OF SOME APPROVED BIOLOGICS MODALITIES AND CELL LINE TYPE
      • FIGURE 42     CELL LINE DEVELOPMENT SERVICES MARKET, BY APPLICATION, (2020 V/S 2028) ($MN)
      • FIGURE 43     CELL LINE DEVELOPMENT SERVCIES GLOBAL MARKET SHARE, BY LEADING PLAYERS (2020) (%)
      • FIGURE 44     KEY DEVELOPMENTS OF CELL LINE DEVELOPMENT MARKET PLAYERS, 2019-2020
      • FIGURE 45     OVERVIEW: ABBVIE INC.
      • FIGURE 46     SWOT: ABBVIE INC.
      • FIGURE 47     SWOT: ABZENA PLC
      • FIGURE 48     OVERVIEW: AGC INC.
      • FIGURE 49     SWOT: AGC INC.
      • FIGURE 50     SWOT: ALBANY MOLECULAR RESEARCH, INC.
      • FIGURE 51     OVERVIEW: BOEHRINGER INGELHEIM
      • FIGURE 52     SWOT: BOEHRINGER INGELHEIM
      • FIGURE 53     OVERVIEW: CATALENT INC.
      • FIGURE 54     SWOT: CATALENT INC.
      • FIGURE 55     OVERVIEW: CHARLES RIVER LABORATORIES
      • FIGURE 56     SWOT: CHARLES RIVER LABORATORIES
      • FIGURE 57     SWOT: COGNATE BIOSERVICES INC.
      • FIGURE 58     SWOT: ENVIGO
      • FIGURE 59     OVERVIEW: EUROFINS SCIENTIFIC
      • FIGURE 60     SWOT: EUROFINS SCIENTIFIC
      • FIGURE 61     OVERVIEW: FUJIFILM HOLDING CORPORATION
      • FIGURE 62     SWOT: FUJIFILM HOLDING CORPORATION
      • FIGURE 63     OVERVIEW: GENSCRIPT BIOTECH CORPORATION
      • FIGURE 64     SWOT: GENSCRIPT BIOSCIENCES CORPORATION
      • FIGURE 65     OVERVIEW: INTERTEK GROUP PLC.
      • FIGURE 66     SWOT: INTERTEK GROUP PLC.
      • FIGURE 67     OVERVIEW: IQVIA HOLDINGS INC.
      • FIGURE 68     SWOT: IQVIA HOLDINGS INC.
      • FIGURE 69     OVERVIEW: JSR CORPORATION
      • FIGURE 70     SWOT: JSR CORPORATION
      • FIGURE 71     OVERVIEW: LABORATORY CORP OF AMERICA HOLDINGS
      • FIGURE 72     SWOT: LABORATORY CORPORATION OF AMERICA HOLDINGS
      • FIGURE 73     OVERVIEW: LONZA GROUP
      • FIGURE 74     SWOT: LONZA GROUP
      • FIGURE 75     OVERVIEW: MERCK KGA
      • FIGURE 76     SWOT: MERCK KGAA
      • FIGURE 77     SWOT: RENTSCHLER BIOPHARMA
      • FIGURE 78     OVERVIEW: SAMSUNG BIOLOGICS
      • FIGURE 79     SWOT: SAMSUNG BIOLOGICS
      • FIGURE 80     OVERVIEW: SARTORIUS
      • FIGURE 81     SWOT: SARTORIUS GROUP
      • FIGURE 82     OVERVIEW: SGS SA
      • FIGURE 83     SWOT: SGS SA
      • FIGURE 84     OVERVIEW: SYNGENE INTERNATIONAL LTD.
      • FIGURE 85     SWOT: SYNGENE INTERNATIONAL
      • FIGURE 86     OVERVIEW: THERMO FISHER SCIENTIFIC
      • FIGURE 87     SWOT: THERMO FISHER SCIENTIFIC
      • FIGURE 88     OVERVIEW: WUXI APPTEC CO., LTD
      • FIGURE 89     SWOT: WUXI APPTEC CO., LTD
      • FIGURE 90     OVERVIEW: WUXI BIOLOGICS
      • FIGURE 91     SWOT: WUXI BIOLOGICS

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     3P Biopharmaceuticals
      • 2     A & G Pharmaceutical Inc (Precision Antibody)
      • 3     Abbvie Inc. (Abbvie Contract Manufacturing)
      • 4     AbSci, LLC
      • 5     Absolute antibody
      • 6     Abzena PLC
      • 7     Adimab, LLC
      • 8     AGC Inc. (AGC Biologics)
      • 9     Agronaut Manufacturing Services
      • 10     Ajinomoto Co. Inc. (Ajinomoto Biopharma services)
      • 11     Albany Molecular Research Inc. (AMRI)
      • 12     Anthem Biosciences Private Limited.
      • 13     Applied StemCell Inc.
      • 14     Avid Bioservices Inc.
      • 15     Axis Biotech Brasil
      • 16     Batavia Biosciences B.V.
      • 17     Binex Co. Ltd.
      • 18     Biodextris
      • 19     BioFactura, Inc
      • 20     Boehringer Ingelheim International GmbH
      • 21     BPS Bioscience, Inc.
      • 22     Catalent Inc.
      • 23     Celonic AG (Glycotope GmbH)
      • 24     Cevec Pharmaceuticals GmbH
      • 25     CEVEC Pharmaceuticals GmbH
      • 26     Charles River Laboratories International Inc.
      • 27     Cognate Bioservices Inc.
      • 28     Creative Biolabs
      • 29     Creative Diagnostics
      • 30     Cytovance Biologics
      • 31     Dyadic International, Inc.
      • 32     EirGenix, Inc.
      • 33     Envigo
      • 34     Eurofins Scientific S.E
      • 35     Evotec
      • 36     Fujifilm Holdings Corporation
      • 37     Fusion Antibodies
      • 38     Genscript Biotech Corporation
      • 39     GVK Biosciences Private Limited
      • 40     Horizon Discovery Ltd.
      • 41     Immunoreagents Inc.
      • 42     Intertek Group plc
      • 43     IQVIA Holdings Inc (Q2 Solutions)
      • 44     JHL biotech Inc.
      • 45     JSR Corporation
      • 46     Kemwell Biopharma
      • 47     Laboratory Corporation of America Holdings
      • 48     Lake Pharma Inc.
      • 49     LFB Biomanufacturing
      • 50     Lonza Group Ltd.
      • 51     Luina Bio Pty Ltd.
      • 52     Merck KGaA (BioReliance)
      • 53     Miltenyi biotec B.V.& Co. KG
      • 54     NeuClone Pty. Ltd.
      • 55     Northway BiotechPharma
      • 56     PanGen Biotech Inc.
      • 57     Premas Biotech Pvt Ltd.
      • 58     ProMab Biotechnologies, Inc
      • 59     Proteogenix
      • 60     Proventus Bio
      • 61     Px'Therapeutics
      • 62     Rentschler Biopharma SE
      • 63     Samsung Biologics Co. Ltd.
      • 64     Sartorious Group
      • 65     SGS SA
      • 66     Sino Biological Inc.
      • 67     Solentim Ltd.
      • 68     Syd labs
      • 69     Syngene International Ltd.
      • 70     The Antibody lab
      • 71     The Menarini Group
      • 72     Therapure Biopharma Inc.
      • 73     Thermo fisher Scientific Inc.
      • 74     Trenzyme GmbH
      • 75     Viva Biotech Ltd.
      • 76     Wacker Chemie AG
      • 77     Waisman clinical biomanufacturing
      • 78     Wuxi Biologics (Cayman) Inc.